Ad
related to: nmda receptor antagonist
Search results
Gilgamesh starts subject dosing in major depressive disorder trial
Clinical Trials Arena via Yahoo Finance· 1 month agoGilgamesh Pharmaceuticals has commenced subject dosing in a Phase IIa clinical trial of GM-1020 to...
Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics AXSM announced that the first patient has been enrolled in the ADVANCE-2 phase...
Black Patients Are Less Likely To Receive Dementia Medications Than White Patients
BuzzFeed News via Yahoo News· 1 year ago“We know that it's not because we're Black and brown that these disparities have occurred. It’s the...
Is Ketamine an Opioid?
Verywell Health via Yahoo News· 5 months agoUnderstanding the differences between these two types of drugs Medically reviewed by Lindsay Cook, PharmD Ketamine is not an opioid. However, it can...
Common Medications Used to Treat Major Depressive Disorder
Verywell Health via Yahoo News· 5 months agoMajor depressive disorder (MDD), also referred to as clinical depression or simply depression, is a...
FDA approves first fast-acting oral drug for clinical depression
The Hill via Yahoo News· 2 years agoStory at a glance A newly approved treatment for clinical depression is being hailed as a potential...
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance· 4 months agoImage source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q4 2023 Earnings Call Feb 20,...
FDA Approves First Fast-Acting Drug for Depression That Works Within 1 Week
Prevention via Yahoo News· 2 years agoThe FDA approves an oral medication to treat clinical depression: Auvelity from Axsome Therapeutics....
20 Cloudiest Cities in the U.S., Ranked
Insider Monkey via Yahoo Finance· 2 months agoIn this article, we will take a look at the top 20 cloudiest cities in the U.S., Ranked. If you would like to skip our discussion on the diverse weather...
2 Top Biotech Stocks to Buy for the Long Haul
Motley Fool· 1 year agoIt has been a rough year for biotech stocks. It doesn't make sense to write off the entire biotech sector, however. Axsome Therapeutics (NASDAQ: AXSM)...
